A Phase 3 interventional study of eloralintide and tirzepatide and Tirzepatide in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Recruiting at 75 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing eloralintide in Obesity — 13 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.
Among the 22 studies testing eloralintide in Obesity, this one is the 6th largest by planned enrollment, is one of 12 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 12 of the 14 other live ones, and was the 20th registered.
11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.
Browse Obesity studies →13 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in Germany, Sweden
Ages 18–70 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–75
Eli Lilly and Company · Sites in United States, Australia, Brazil and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Belgium and 11 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 12 started in 2026.
This study's planned enrollment of 1,000 is above the median of 67 across 9,027 interventional studies indexed under Obesity.
Median enrollment 315 across the 22 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 30 open now, 54 under way, 30 of them phase 3. Of 62 finished, 29 (47%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 16th largest by planned enrollment of the 117 interventional ones that give a count, is one of 25 that started in 2026, is one of 51 in phase 3, reaches primary completion later than 50 of the 53 other live ones, and was the 113th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
7 of the studies testing eloralintide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07215559Eli Lilly and CompanyA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | 2027-03 |
| NCT07808060Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight | 2027-06 |
| NCT07765511Eli Lilly and CompanyA Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes | 2027-06 |
| NCT07665879Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity | 2027-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 22 studies testing eloralintide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.
Participation in the study will last about 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have taken any of the following within 90 days prior to screening
Have had within 90 days prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive EloraTZP subcutaneously (SC)
Drug: eloralintide and tirzepatide
Participants will receive tirzepatide SC
Drug: Tirzepatide
Drug pages: Eloralintide · Tirzepatide
Administered SC
Also known as: LY900043
Administered SC
Also known as: LY3298176
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 100
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 100
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 100
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 100
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 100
Percent Change from Baseline in Total Body Fat Mass
Time frame: Baseline, Week 100
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 100
Change from Baseline in Fasting Glucose
Time frame: Baseline, Week 100
Percentage of Participants who Achieve a Composite of Body Weight Reduction ≥ 15% and HbA1c <6.5%
Time frame: Week 100
Percent Change from Baseline in Total Cholesterol
Time frame: Baseline, Week 100
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 100
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 100
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) Total Score
Time frame: Baseline, Week 100
Change from Baseline in EQ-5D-5L Score
Time frame: Baseline, Week 100
Change from Baseline in Eating Behaviors and Attitudes Questionnaire (EBAQ) Score
Time frame: Baseline, Week 100
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Time frame: Baseline, Week 100
Percentage of Participants with a Change in Medication Use
Time frame: Baseline, Week 100
Overall Functional Assessment of Chronic Illness Therapy, Item GP5 (FACT-GP5) Score
Time frame: Week 100
Pharmacokinetics (PK): Maximum Concentration of Eloralintide at Steady State (Cmax,ss)
Time frame: Baseline through Week 100
PK: Area Under the Concentration Versus Time Curve of Eloralintide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Time frame: Baseline through Week 100
PK: Maximum Concentration of Tirzepatide at Steady State (Cmax,ss)
Time frame: Baseline through Week 100
PK: Area Under the Concentration Versus Time Curve of Tirzepatide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Time frame: Baseline through Week 100
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Oct 2026 (actual). Primary completion is estimated for Oct 2029, 36 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 36 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eloralintide · Tirzepatide